Business, energy, technology, markets and global industry news from Business News Today

Pharma & Biotech

PharmaDeviceNews Pharma & Biotech
Researchers examine blood-based RNA biomarkers that could eventually support more objective assessment and treatment monitoring for neuropathic pain, as Lilac Biosciences and Soin Neuroscience outline a translational testing roadmap. Representative image.
Pharma & Biotech

Lilac Biosciences and Soin Neuroscience publish RNA biomarker review for neuropathic pain

Lilac Biosciences and Soin Neuroscience map an RNA biomarker path for neuropathic pain, but clinical validation remains the decisive test.

Read More
ArkBio’s completion of Phase I dosing for AK0406 moves the investigational long-acting influenza prophylaxis candidate into extended safety, pharmacokinetic and immunogenicity follow-up. Representative image.
Pharma & Biotech

What does ArkBio’s AK0406 dosing milestone mean for long-acting influenza prevention?

ArkBio has dosed all Phase I cohorts of AK0406, moving the long-acting influenza prophylaxis candidate into six-month safety follow-up.

Read More
Laminar Pharma’s LAM561 Phase 2b/3 glioblastoma trial has completed its final patient visit, moving the investigational therapy toward a pivotal overall survival readout expected in 2027. Representative image.
Pharma & Biotech

Laminar Pharma has finished patient follow-up. Now one survival result will decide LAM561’s future

Laminar Pharma completes LAM561 trial follow-up as the glioblastoma study advances toward a pivotal overall survival readout in 2027.

Read More
A biotechnology researcher conducts precision laboratory testing as Thyora Therapeutics advances its next-generation covalent drug discovery platform built around bicyclobutane chemistry, chemoproteomics and oncology-focused medicine development. Representative image.
Pharma & Biotech

Can Thyora Therapeutics turn a strained four-carbon ring into safer covalent cancer drugs?

Thyora Therapeutics launches a Science-backed covalent drug platform, but its first candidate and clinical development timeline remain undisclosed.

Read More
Students practise precision pipetting in a biotechnology laboratory, reflecting BioBuilder Educational Foundation’s nearly $1 million Massachusetts grant to develop AI-guided laboratory skills training for high school learners. Representative image.
Pharma & Biotech

BioBuilder secures nearly $1m Massachusetts grant for AI-guided biotech training

BioBuilder’s nearly $1 million Massachusetts grant will test AI coaching for biotech laboratory skills in an initial pilot reaching about 850 students.

Read More
A clinician reviews lymphoma treatment data as Genmab and AbbVie clarify that the Phase 3 EPCORE DLBCL-1 trial missed its sole United States overall survival endpoint despite a progression-free survival benefit for epcoritamab. Representative image.
Pharma & Biotech

Genmab and AbbVie clarify EPCORE DLBCL-1 missed sole US overall survival endpoint

Genmab and AbbVie clarify that EPCORE DLBCL-1 missed its sole US overall survival endpoint despite a PFS benefit for epcoritamab.

Read More
Summit Therapeutics enters a pivotal phase for ivonescimab as the oncology developer deploys its $690.7 million cash position toward an upcoming FDA decision, HARMONi-3 data and an expanding late-stage lung cancer programme. Representative image.
Pharma & Biotech

Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything

Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.

Read More
GE HealthCare’s CFO transition and preliminary second-quarter 2026 revenue growth place leadership continuity, earnings momentum and reaffirmed guidance in focus ahead of its full results. Representative image.
Pharma & Biotech

What GE HealthCare’s CFO transition means before its July 29 earnings report

GE HealthCare names George Newcomb interim CFO as preliminary Q2 revenue rises 5.7% and 2026 guidance holds before July 29 results.

Read More
Calocurb clinical trial finds weight and fat reduction without measured muscle loss
Pharma & Biotech

Can a bitter hop supplement protect muscle during weight loss? Calocurb trial offers an early answer

A 24-week Calocurb trial found 4.3% weight loss and reduced fat without measured muscle loss, but important evidence limitations remain.

Read More
Representative image: Corporate and clinical teams review melanoma trial data as Scancell moves to acquire Neuphoria Therapeutics $NEUP and secure up to $89 million to fund the Phase 3 iSCIB1+ immunotherapy program.
Pharma & Biotech

Scancell secures path to $89m financing through Neuphoria Therapeutics merger

Scancell will acquire Neuphoria Therapeutics and pursue up to $89 million to fund the Phase 3 iSCIB1+ melanoma trial through 2028.

Read More